Department of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, PR China.
Department of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, PR China; Anhui Province Key Laboratory of Chinese Medicinal Formula, Anhui University of Chinese Medicine, Hefei, 230012, PR China; Institute of Traditional Chinese Medicine Resources Protection and Development, Anhui Academy of Chinese Medicine, Hefei, 230012, PR China.
J Ethnopharmacol. 2022 Jan 30;283:114705. doi: 10.1016/j.jep.2021.114705. Epub 2021 Oct 14.
Dan-Deng-Tong-Nao Capsules (DDTNC) is a Chinese patent medicine and has been used in treating cerebral ischemic stroke (IS) for a long time in China, protection of brain microvascular endothelial cells (BMECs) is the main treatment strategy. But the holistic chemical information and potential bioactive components of DDTNC on protecting BMECs and its underlying mechanism is still unclear.
To identify the active ingredients of DDTNC and to explore the protective effects of DDTNC on BMECs associated with Wnt/β-catenin pathway.
The components of DDTNC and cerebrospinal fluid containing composition of DDTNC (DDTNC-CSF) were detected by High performance liquid chromatography combined with Diode array detector (HPLC-DAD) and Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS), respectively. The experiment rat model was established with middle cerebral artery occlusion (MCAO), the therapeutic effects of DDTNC were assessed by Longa assay and TTC staining. The cerebral micro vessel density was determined by immunofluorescence staining. The injured BMECs caused by oxygen-glucose deprivation and reperfusion (OGD/R) was used to evaluate the protective effect of cerebrospinal fluid containing composition of DDTNC (DDTNC-CSF). The cell survival rate was detected by the method of CCK-8, the intracellular Ca and reactive oxygen species (ROS) was estimated by Fluo-3. Moreover, the proteins of Bax, Bcl-2, Wnt, β-catenin, GSK-3β was determined by Western blotting.
The RSD values of all methodological studies were less than 3.0%. A total of 20 compounds were detected under the optimized HPLC-DAD chromatographic condition. In the UPLC-Q-TOF-MS negative mode, peak 1 and peak 2 were detecteted in DDTNC-CSF and was identified as Danshensu and Puerarin, respectively. In the UPLC-Q-TOF-MS positive mode, peak 1 and peak 3 were detecteted in DDTNC-CSF and was identified as Danshensu and Scutellarin, respectively. DDTNC significantly decreased the Longa values and infarct volume and significantly increased the cerebral microvessel density of the MCAO rats. The accumulation of intracellular Ca and ROS in BMECs injured by OGD/R decreased significantly in DDTNC-CSF group. The expression of Bcl-2, β-catenin, wnt-1 was upregulated by DDTNC-CSF and the level of Bax and GSK3β could be downregulated by DDTNC-CSF.
The present study provided a scientific basis for revealing the mechanism of DDTNC in the treatment of IS and DDTNC is expected to be an effective drug for the treatment of IS.
丹灯通脑胶囊(DDTNC)是一种中药,在中国长期用于治疗缺血性脑卒中(IS),保护脑微血管内皮细胞(BMECs)是主要的治疗策略。但是,DDTNC 对 BMECs 的整体化学信息和潜在生物活性成分及其潜在机制仍不清楚。
鉴定 DDTNC 的活性成分,并探讨 DDTNC 对与 Wnt/β-catenin 通路相关的 BMECs 的保护作用。
采用高效液相色谱法结合二极管阵列检测器(HPLC-DAD)和超高效液相色谱-四极杆飞行时间质谱法(UPLC-Q-TOF-MS)分别检测 DDTNC 的成分和脑脊液中含有的 DDTNC(DDTNC-CSF)的成分。采用大脑中动脉闭塞(MCAO)建立实验大鼠模型,通过 Longa 评分和 TTC 染色评估 DDTNC 的治疗效果。通过免疫荧光染色测定脑微血管密度。用氧葡萄糖剥夺再灌注(OGD/R)损伤 BMECs 来评估含 DDTNC 脑脊液(DDTNC-CSF)的保护作用。用 CCK-8 法检测细胞存活率,用 Fluo-3 法估计细胞内 Ca 和活性氧(ROS)。此外,用 Western blot 法测定 Bax、Bcl-2、Wnt、β-catenin、GSK-3β 蛋白。
所有方法学研究的 RSD 值均小于 3.0%。在优化的 HPLC-DAD 色谱条件下共检测到 20 种化合物。在 UPLC-Q-TOF-MS 负离子模式下,在 DDTNC-CSF 中检测到峰 1 和峰 2,分别鉴定为丹参素和葛根素。在 UPLC-Q-TOF-MS 正离子模式下,在 DDTNC-CSF 中检测到峰 1 和峰 3,分别鉴定为丹参素和野黄芩苷。DDTNC 可显著降低 MCAO 大鼠的 Longa 值和梗死体积,显著增加大脑中动脉闭塞大鼠的脑微血管密度。DDTNC-CSF 可显著减少 OGD/R 损伤的 BMECs 中细胞内 Ca 和 ROS 的积累。DDTNC-CSF 可上调 Bcl-2、β-catenin、wnt-1 的表达,并可下调 Bax 和 GSK3β 的水平。
本研究为揭示 DDTNC 治疗 IS 的机制提供了科学依据,DDTNC 有望成为治疗 IS 的有效药物。